Arcus Biosciences (RCUS) Gets a Buy Rating from Leerink Partners

In a report released yesterday, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcus Biosciences (RCUSResearch Report). The company’s shares closed last Friday at $36.50.

According to, Graybosch is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.1% and a 29.2% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Bolt Biotherapeutics, F-star Therapeutics, and Nektar Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcus Biosciences with a $59.75 average price target, representing a 68.3% upside. In a report issued on February 11, Berenberg Bank also maintained a Buy rating on the stock with a $68.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $49.10 and a one-year low of $22.36. Currently, Arcus Biosciences has an average volume of 649.8K.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCUS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Read More on RCUS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More